Chin-Hsien Lin1, Cheng-Hsuan Li1, Kai-Chien Yang1, Fang-Ju Lin1, Chau-Chung Wu1, Jen-Jie Chieh1, Ming-Jang Chiu2. 1. From the Department of Neurology (C.-H.L., C.-H.L., M.-J.C.), Department of Internal Medicine (K.-C.Y., C.-C.W.), and Department of Pharmacy (F.-J.L.), National Taiwan University Hospital, College of Medicine, National Taiwan University; Department of Pharmacology (K.-C.Y.), Graduate Institute of Clinical Pharmacy & School of Pharmacy (F.-J.L.), and Graduate Institute of Brain and Mind Sciences (M.-J.C.), College of Medicine, National Taiwan University; Institute of Electro-Optical Science and Technology (J.-J.C.), National Taiwan Normal University; and Graduate Institute of Biomedical Engineering and Bioinformatics (M.-J.C.) and Graduate Institute of Psychology (M.-J.C.), National Taiwan University, Taipei. 2. From the Department of Neurology (C.-H.L., C.-H.L., M.-J.C.), Department of Internal Medicine (K.-C.Y., C.-C.W.), and Department of Pharmacy (F.-J.L.), National Taiwan University Hospital, College of Medicine, National Taiwan University; Department of Pharmacology (K.-C.Y.), Graduate Institute of Clinical Pharmacy & School of Pharmacy (F.-J.L.), and Graduate Institute of Brain and Mind Sciences (M.-J.C.), College of Medicine, National Taiwan University; Institute of Electro-Optical Science and Technology (J.-J.C.), National Taiwan Normal University; and Graduate Institute of Biomedical Engineering and Bioinformatics (M.-J.C.) and Graduate Institute of Psychology (M.-J.C.), National Taiwan University, Taipei. mjchiu@ntu.edu.tw.
Abstract
OBJECTIVE: To examine whether plasma neurofilament light chain (NfL) levels were associated with motor and cognitive progression in Parkinson disease (PD). METHODS: This prospective follow-up study enrolled 178 participants, including 116 with PD, 22 with multiple system atrophy (MSA), and 40 healthy controls. We measured plasma NfL levels with electrochemiluminescence immunoassay. Patients with PD received evaluations of motor and cognition at baseline and at a mean follow-up interval of 3 years. Changes in the Unified Parkinson's Disease Rating Scale (UPDRS) part III motor score and Mini-Mental State Examination score were used to assess motor and cognition progression. RESULTS: Plasma NfL levels were significantly higher in the MSA group than in the PD and healthy groups (35.8 ± 6.2, 17.6 ± 2.8, and 10.6 ± 2.3 pg/mL, respectively, p < 0.001). In the PD group, NfL levels were significantly elevated in patients with advanced Hoehn-Yahr stage and patients with dementia (p < 0.001). NfL levels were modestly correlated with UPDRS part III scores (r = 0.42, 95% confidence interval 0.46-0.56, p < 0.001). After a mean follow-up of 3.4 ± 1.2 years, a Cox regression analysis adjusted for age, sex, disease duration, and baseline motor or cognitive status showed that higher baseline NfL levels were associated with higher risks for either motor or cognition progression (p = 0.029 and p = 0.015, respectively). CONCLUSIONS: Plasma NfL levels correlated with disease severity and progression in terms of both motor and cognitive functions in PD. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that plasma NfL level distinguishes PD from MSA and is a surrogate biomarker for PD progression.
OBJECTIVE: To examine whether plasma neurofilament light chain (NfL) levels were associated with motor and cognitive progression in Parkinson disease (PD). METHODS: This prospective follow-up study enrolled 178 participants, including 116 with PD, 22 with multiple system atrophy (MSA), and 40 healthy controls. We measured plasma NfL levels with electrochemiluminescence immunoassay. Patients with PD received evaluations of motor and cognition at baseline and at a mean follow-up interval of 3 years. Changes in the Unified Parkinson's Disease Rating Scale (UPDRS) part III motor score and Mini-Mental State Examination score were used to assess motor and cognition progression. RESULTS: Plasma NfL levels were significantly higher in the MSA group than in the PD and healthy groups (35.8 ± 6.2, 17.6 ± 2.8, and 10.6 ± 2.3 pg/mL, respectively, p < 0.001). In the PD group, NfL levels were significantly elevated in patients with advanced Hoehn-Yahr stage and patients with dementia (p < 0.001). NfL levels were modestly correlated with UPDRS part III scores (r = 0.42, 95% confidence interval 0.46-0.56, p < 0.001). After a mean follow-up of 3.4 ± 1.2 years, a Cox regression analysis adjusted for age, sex, disease duration, and baseline motor or cognitive status showed that higher baseline NfL levels were associated with higher risks for either motor or cognition progression (p = 0.029 and p = 0.015, respectively). CONCLUSIONS: Plasma NfL levels correlated with disease severity and progression in terms of both motor and cognitive functions in PD. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that plasma NfL level distinguishes PD from MSA and is a surrogate biomarker for PD progression.
Authors: Rasmus Rydbirk; Ole Østergaard; Jesper V Olsen; Susana Aznar; Jonas Folke; Casper Hempel; Brian DellaValle; Thomas L Andresen; Annemette Løkkegaard; Anne-Mette Hejl; Matthias Bode; Morten Blaabjerg; Mette Møller; Erik H Danielsen; Lisette Salvesen; Charlotte C Starhof; Sara Bech; Kristian Winge; Jørgen Rungby; Bente Pakkenberg; Tomasz Brudek Journal: Cell Mol Life Sci Date: 2022-06-03 Impact factor: 9.207
Authors: Nirosen Vijiaratnam; Michael Lawton; Amanda J Heslegrave; Tong Guo; Manuela Tan; Edwin Jabbari; Raquel Real; John Woodside; Katherine Grosset; Viorica Chelban; Dilan Athauda; Christine Girges; Roger A Barker; John Hardy; Nicholas Wood; Henry Houlden; Nigel Williams; Yoav Ben-Shlomo; Henrik Zetterberg; Donald G Grosset; Thomas Foltynie; Huw R Morris Journal: J Neurol Neurosurg Psychiatry Date: 2022-05-16 Impact factor: 13.654
Authors: Rong Ye; Joseph J Locascio; Anna E Goodheart; Moqing Quan; Baorong Zhang; Stephen N Gomperts Journal: Parkinsonism Relat Disord Date: 2021-02-17 Impact factor: 4.891
Authors: Kumar B Rajan; Neelum T Aggarwal; Elizabeth A McAninch; Jennifer Weuve; Lisa L Barnes; Robert S Wilson; Charles DeCarli; Denis A Evans Journal: Ann Neurol Date: 2020-09-29 Impact factor: 11.274